prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-ons...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2009-04, Vol.114 (3), p.457-462 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 462 |
---|---|
container_issue | 3 |
container_start_page | 457 |
container_title | Breast cancer research and treatment |
container_volume | 114 |
creator | Cao, A-Yong Huang, Juan Hu, Zhen Li, Wen-Feng Ma, Zhong-Liang Tang, Li-Li Zhang, Bin Su, Feng-Xi Zhou, Jie Di, Gen-Hong Shen, Kun-Wei Wu, Jiong Lu, Jin-Song Luo, Jian-Min Yuan, Wen-Tao Shen, Zhen-Zhou Huang, Wei Shao, Zhi-Ming |
description | PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population. |
doi_str_mv | 10.1007/s10549-008-0036-z |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66965426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66965426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</originalsourceid><addsrcrecordid>eNp9kUlvFDEQhS0EIkPgB3ABKxLcmpSX9nKcjNikkUBAzpa7uzzpqJfB7k6U3PjneOgRkThwcPlQ33tVqkfISwbvGIA-TwxKaQsAk59Qxf0jsmKlFoXmTD8mK2BKF8qAOiHPUroGAKvBPiUnzEippFAr8msf8cZ3ONRIx0C_rrcXnO4w9l07IO3nyU_tOCTaDvTi22bNzg-V0wF3uXGDdHOVuYT0duxxoLftdEXRx-6OZhFOtIro00Rrn_0jHSP1IWA9YUMjdn8c0nPyJPgu4Yvjf0ouP7z_sflUbL98_LxZb4tacjEVNTTaSFZVCJYHqZCbRlluK9HwqgRVV6W3IohgQqUVmJI3AbkArkujhefilLxdfPdx_Dljmlzfphq7zg84zskpZVUpucrg2T_g9TjHIe_mOOPSSJAsQ2yB6jimFDG4fWx7H-8cA3cIxy3huByOO4Tj7rPm1dF4rnpsHhTHNDLw5gj4VPsuxHy2Nv3l8nTOjRWZ4wuXcmvIaT1s-L_prxdR8KPzu5iNL79zYAJYaa3gpfgNmAKvpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212484041</pqid></control><display><type>article</type><title>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Cao, A-Yong ; Huang, Juan ; Hu, Zhen ; Li, Wen-Feng ; Ma, Zhong-Liang ; Tang, Li-Li ; Zhang, Bin ; Su, Feng-Xi ; Zhou, Jie ; Di, Gen-Hong ; Shen, Kun-Wei ; Wu, Jiong ; Lu, Jin-Song ; Luo, Jian-Min ; Yuan, Wen-Tao ; Shen, Zhen-Zhou ; Huang, Wei ; Shao, Zhi-Ming</creator><creatorcontrib>Cao, A-Yong ; Huang, Juan ; Hu, Zhen ; Li, Wen-Feng ; Ma, Zhong-Liang ; Tang, Li-Li ; Zhang, Bin ; Su, Feng-Xi ; Zhou, Jie ; Di, Gen-Hong ; Shen, Kun-Wei ; Wu, Jiong ; Lu, Jin-Song ; Luo, Jian-Min ; Yuan, Wen-Tao ; Shen, Zhen-Zhou ; Huang, Wei ; Shao, Zhi-Ming</creatorcontrib><description>PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-008-0036-z</identifier><identifier>PMID: 18446436</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adult ; Age of Onset ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Breast cancer ; breast neoplasms ; Breast Neoplasms - epidemiology ; Breast Neoplasms - genetics ; Cancer research ; Cancer therapies ; China ; Chinese ; DHPLC ; Family Health ; Fanconi Anemia Complementation Group N Protein ; Female ; General aspects (metabolism, cell proliferation, established cell line...) ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic disorders ; Germ-Line Mutation ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Nuclear Proteins - genetics ; Oncology ; PALB2 ; Population genetics ; Preclinical Study ; Prevalence ; Sequence variation ; Tumor cell ; Tumor Suppressor Proteins - genetics ; Tumors</subject><ispartof>Breast cancer research and treatment, 2009-04, Vol.114 (3), p.457-462</ispartof><rights>Springer Science+Business Media, LLC. 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</citedby><cites>FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-008-0036-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-008-0036-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21222893$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18446436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, A-Yong</creatorcontrib><creatorcontrib>Huang, Juan</creatorcontrib><creatorcontrib>Hu, Zhen</creatorcontrib><creatorcontrib>Li, Wen-Feng</creatorcontrib><creatorcontrib>Ma, Zhong-Liang</creatorcontrib><creatorcontrib>Tang, Li-Li</creatorcontrib><creatorcontrib>Zhang, Bin</creatorcontrib><creatorcontrib>Su, Feng-Xi</creatorcontrib><creatorcontrib>Zhou, Jie</creatorcontrib><creatorcontrib>Di, Gen-Hong</creatorcontrib><creatorcontrib>Shen, Kun-Wei</creatorcontrib><creatorcontrib>Wu, Jiong</creatorcontrib><creatorcontrib>Lu, Jin-Song</creatorcontrib><creatorcontrib>Luo, Jian-Min</creatorcontrib><creatorcontrib>Yuan, Wen-Tao</creatorcontrib><creatorcontrib>Shen, Zhen-Zhou</creatorcontrib><creatorcontrib>Huang, Wei</creatorcontrib><creatorcontrib>Shao, Zhi-Ming</creatorcontrib><title>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.</description><subject>Adult</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>breast neoplasms</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - genetics</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>China</subject><subject>Chinese</subject><subject>DHPLC</subject><subject>Family Health</subject><subject>Fanconi Anemia Complementation Group N Protein</subject><subject>Female</subject><subject>General aspects (metabolism, cell proliferation, established cell line...)</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Genetic disorders</subject><subject>Germ-Line Mutation</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Nuclear Proteins - genetics</subject><subject>Oncology</subject><subject>PALB2</subject><subject>Population genetics</subject><subject>Preclinical Study</subject><subject>Prevalence</subject><subject>Sequence variation</subject><subject>Tumor cell</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUlvFDEQhS0EIkPgB3ABKxLcmpSX9nKcjNikkUBAzpa7uzzpqJfB7k6U3PjneOgRkThwcPlQ33tVqkfISwbvGIA-TwxKaQsAk59Qxf0jsmKlFoXmTD8mK2BKF8qAOiHPUroGAKvBPiUnzEippFAr8msf8cZ3ONRIx0C_rrcXnO4w9l07IO3nyU_tOCTaDvTi22bNzg-V0wF3uXGDdHOVuYT0duxxoLftdEXRx-6OZhFOtIro00Rrn_0jHSP1IWA9YUMjdn8c0nPyJPgu4Yvjf0ouP7z_sflUbL98_LxZb4tacjEVNTTaSFZVCJYHqZCbRlluK9HwqgRVV6W3IohgQqUVmJI3AbkArkujhefilLxdfPdx_Dljmlzfphq7zg84zskpZVUpucrg2T_g9TjHIe_mOOPSSJAsQ2yB6jimFDG4fWx7H-8cA3cIxy3huByOO4Tj7rPm1dF4rnpsHhTHNDLw5gj4VPsuxHy2Nv3l8nTOjRWZ4wuXcmvIaT1s-L_prxdR8KPzu5iNL79zYAJYaa3gpfgNmAKvpw</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Cao, A-Yong</creator><creator>Huang, Juan</creator><creator>Hu, Zhen</creator><creator>Li, Wen-Feng</creator><creator>Ma, Zhong-Liang</creator><creator>Tang, Li-Li</creator><creator>Zhang, Bin</creator><creator>Su, Feng-Xi</creator><creator>Zhou, Jie</creator><creator>Di, Gen-Hong</creator><creator>Shen, Kun-Wei</creator><creator>Wu, Jiong</creator><creator>Lu, Jin-Song</creator><creator>Luo, Jian-Min</creator><creator>Yuan, Wen-Tao</creator><creator>Shen, Zhen-Zhou</creator><creator>Huang, Wei</creator><creator>Shao, Zhi-Ming</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090401</creationdate><title>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</title><author>Cao, A-Yong ; Huang, Juan ; Hu, Zhen ; Li, Wen-Feng ; Ma, Zhong-Liang ; Tang, Li-Li ; Zhang, Bin ; Su, Feng-Xi ; Zhou, Jie ; Di, Gen-Hong ; Shen, Kun-Wei ; Wu, Jiong ; Lu, Jin-Song ; Luo, Jian-Min ; Yuan, Wen-Tao ; Shen, Zhen-Zhou ; Huang, Wei ; Shao, Zhi-Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>breast neoplasms</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - genetics</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>China</topic><topic>Chinese</topic><topic>DHPLC</topic><topic>Family Health</topic><topic>Fanconi Anemia Complementation Group N Protein</topic><topic>Female</topic><topic>General aspects (metabolism, cell proliferation, established cell line...)</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Genetic disorders</topic><topic>Germ-Line Mutation</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Nuclear Proteins - genetics</topic><topic>Oncology</topic><topic>PALB2</topic><topic>Population genetics</topic><topic>Preclinical Study</topic><topic>Prevalence</topic><topic>Sequence variation</topic><topic>Tumor cell</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, A-Yong</creatorcontrib><creatorcontrib>Huang, Juan</creatorcontrib><creatorcontrib>Hu, Zhen</creatorcontrib><creatorcontrib>Li, Wen-Feng</creatorcontrib><creatorcontrib>Ma, Zhong-Liang</creatorcontrib><creatorcontrib>Tang, Li-Li</creatorcontrib><creatorcontrib>Zhang, Bin</creatorcontrib><creatorcontrib>Su, Feng-Xi</creatorcontrib><creatorcontrib>Zhou, Jie</creatorcontrib><creatorcontrib>Di, Gen-Hong</creatorcontrib><creatorcontrib>Shen, Kun-Wei</creatorcontrib><creatorcontrib>Wu, Jiong</creatorcontrib><creatorcontrib>Lu, Jin-Song</creatorcontrib><creatorcontrib>Luo, Jian-Min</creatorcontrib><creatorcontrib>Yuan, Wen-Tao</creatorcontrib><creatorcontrib>Shen, Zhen-Zhou</creatorcontrib><creatorcontrib>Huang, Wei</creatorcontrib><creatorcontrib>Shao, Zhi-Ming</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, A-Yong</au><au>Huang, Juan</au><au>Hu, Zhen</au><au>Li, Wen-Feng</au><au>Ma, Zhong-Liang</au><au>Tang, Li-Li</au><au>Zhang, Bin</au><au>Su, Feng-Xi</au><au>Zhou, Jie</au><au>Di, Gen-Hong</au><au>Shen, Kun-Wei</au><au>Wu, Jiong</au><au>Lu, Jin-Song</au><au>Luo, Jian-Min</au><au>Yuan, Wen-Tao</au><au>Shen, Zhen-Zhou</au><au>Huang, Wei</au><au>Shao, Zhi-Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>114</volume><issue>3</issue><spage>457</spage><epage>462</epage><pages>457-462</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>18446436</pmid><doi>10.1007/s10549-008-0036-z</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2009-04, Vol.114 (3), p.457-462 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_proquest_miscellaneous_66965426 |
source | MEDLINE; SpringerNature Journals |
subjects | Adult Age of Onset Aged Aged, 80 and over Biological and medical sciences Breast cancer breast neoplasms Breast Neoplasms - epidemiology Breast Neoplasms - genetics Cancer research Cancer therapies China Chinese DHPLC Family Health Fanconi Anemia Complementation Group N Protein Female General aspects (metabolism, cell proliferation, established cell line...) Genes, BRCA1 Genes, BRCA2 Genetic disorders Germ-Line Mutation Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Mutation Nuclear Proteins - genetics Oncology PALB2 Population genetics Preclinical Study Prevalence Sequence variation Tumor cell Tumor Suppressor Proteins - genetics Tumors |
title | prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A46%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=prevalence%20of%20PALB2%20germline%20mutations%20in%20BRCA1/BRCA2%20negative%20Chinese%20women%20with%20early%20onset%20breast%20cancer%20or%20affected%20relatives&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Cao,%20A-Yong&rft.date=2009-04-01&rft.volume=114&rft.issue=3&rft.spage=457&rft.epage=462&rft.pages=457-462&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-008-0036-z&rft_dat=%3Cproquest_cross%3E66965426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212484041&rft_id=info:pmid/18446436&rfr_iscdi=true |